Cover Image
市場調查報告書

天皰瘡 - 開發中產品分析

Pemphigus - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255976
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
天皰瘡 - 開發中產品分析 Pemphigus - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 69 Pages
簡介

天皰瘡是皮膚、口腔內、生殖器等敿膜出現水皰的罕見皮膚疾病。症狀有水痘,疼痛,發燒,寒氣,肌肉或關節的疼痛等,高齡是發病原因。

本報告提供天皰瘡的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

天皰瘡概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Clinuvel Pharmaceuticals Limited
  • Genmab A/S
  • HanAll Biopharma Co., Ltd.
  • Immunomedics, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • PinCell srl

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • afamelanotide
  • Antibody for Autoimmune Disorders and Inflammation
  • DP-C006
  • Drugs to Target HSP27 for Autoimmune Disorders
  • HL-161
  • ofatumumab
  • PC-111
  • VAY-736
  • veltuzumab
  • afamelanotide
  • Antibody for Autoimmune Disorders and Inflammation
  • DP-C006
  • Drugs to Target HSP27 for Autoimmune Disorders
  • HL-161
  • ofatumumab
  • PC-111
  • VAY-736
  • veltuzumab

最新的開發平台資訊

開發暫停中的計劃

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7137IDB

Summary

Global Markets Direct's, 'Pemphigus - Pipeline Review, H2 2015', provides an overview of the Pemphigus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pemphigus
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pemphigus and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pemphigus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pemphigus pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pemphigus
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pemphigus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pemphigus Overview
  • Therapeutics Development
    • Pipeline Products for Pemphigus - Overview
    • Pipeline Products for Pemphigus - Comparative Analysis
  • Pemphigus - Therapeutics under Development by Companies
  • Pemphigus - Therapeutics under Investigation by Universities/Institutes <
  • Pemphigus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Pemphigus - Products under Development by Companies
  • Pemphigus - Products under Investigation by Universities/Institutes
  • Pemphigus - Companies Involved in Therapeutics Development
    • Almirall, S.A.
    • Biogen, Inc.
    • Genmab A/S
    • HanAll Biopharma Co., Ltd.
    • Immunomedics, Inc.
    • Momenta Pharmaceuticals, Inc.
    • Novartis AG
    • PinCell srl
  • Pemphigus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADP-31415 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DP-C006 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ofatumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PC-111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-Cell Therapy for Pemphigus Vulgaris - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAY-736 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pemphigus - Recent Pipeline Updates
  • Pemphigus - Dormant Projects
  • Pemphigus - Product Development Milestones
    • Featured News & Press Releases
      • Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris
      • Nov 21, 2014: Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus
      • Oct 07, 2014: Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris
      • Jul 04, 2013: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pemphigus, H2 2015
  • Number of Products under Development for Pemphigus - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Pemphigus - Pipeline by Almirall, S.A., H2 2015
  • Pemphigus - Pipeline by Biogen, Inc., H2 2015
  • Pemphigus - Pipeline by Genmab A/S, H2 2015
  • Pemphigus - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Pemphigus - Pipeline by Immunomedics, Inc., H2 2015
  • Pemphigus - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015
  • Pemphigus - Pipeline by Novartis AG, H2 2015
  • Pemphigus - Pipeline by PinCell srl, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Pemphigus Therapeutics - Recent Pipeline Updates, H2 2015
  • Pemphigus - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Pemphigus, H2 2015
  • Number of Products under Development for Pemphigus - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top